– USA, CT – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company today announced the appointment of Christine Nash and Dr. Hui Liu (Ph.D.) to its Board of Directors.
“Christine’s commercial and product launch experience in rare diseases and Hui’s industry experience in business development and finance will be an asset to our Board as Rallybio continues to advance its current product portfolio and bring additional candidates into our pipeline. We look forward to their valuable expertise and business insights. On behalf of our directors, I am pleased to welcome Christine and Hui to Rallybio’s Board,” said Chairman and CEO, Dr. Martin Mackay.
Concurrently, the company announced the resignation of Dr. Tim Shannon effective at the 2022 AGM.
About Christine Nash
Christine Nash is an accomplished biopharmaceutical industry leader with nearly 20 years of commercial and product launch experience in rare diseases. She currently serves as Board Chair and senior advisor to the President and CEO at The CM Group, an integrated healthcare agency providing scientific and commercialization strategies and services to the life sciences industry, and Principal at Chatiemac Consulting, LLC, a firm which provides strategic and commercial planning guidance to biotech companies developing medications for rare diseases. Before this, she was at Hyperion Therapeutics, Inc., where she held roles of increasing responsibility in marketing and business development before becoming Chief Commercial Officer. As Chief Commercial Officer, she led the commercialization of two products (RAVICTI and BUPHENYL) for urea cycle disorders, an ultra-orphan disease, until its acquisition by Horizon Pharma. Before Hyperion, Ms. Nash held marketing roles at Cotherix, Inc., where she developed and led the product launch campaign for Ventavis®, for the treatment of pulmonary arterial hypertension, until its acquisition by Actelion. Early in her career, she was a Product Manager at Genesoft Pharmaceuticals until its acquisition by Oscient Pharmaceuticals.
“I have spent the bulk of my career focused on the commercialization of products in the rare disease space, and I am excited to join Hui and Rallybio’s Board of Directors during this exciting period of growth for the Company. I look forward to utilizing my background and prior experience to contribute to the Board and the Rallybio team as the Company develops the global commercial strategy for its pipeline of rare disease product candidates,” said Christine Nash.
Ms. Nash holds a Master of Business Administration and Bachelor of Arts with Honors in Public Policy from Stanford University.
About Dr. Hui Liu
Dr. Hui Liu is a seasoned biopharma executive with 25 years of experience in business development, finance, and strategy. He is currently the Executive Vice President, Chief Business Officer, and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company engaged in developing multispecific antibody therapeutics. Before Merus, he was the Global Head of Business Development & Licensing at Novartis Oncology. Before this, Dr. Liu served as Global Head of Business Development and Licensing for Novartis Vaccines & Diagnostics. Dr. Liu began his pharma career in business development at Pfizer where he held roles of increasing responsibility. Before Pfizer, he worked in investment banking at Citigroup and Goldman Sachs.
Dr. Liu commented, “I am delighted to join Christine and Rallybio’s Board of Directors and collaborate with the Board and the Rallybio team to support their mission of bringing hope to patients suffering from rare diseases. I look forward to utilizing my experience to contribute to the Company’s growth, particularly in the area of business development strategy and execution as the team builds Rallybio’s pipeline.”
Dr. Liu holds a Bachelor of Science in Biology from Peking University in Beijing, China, and both a Master of Business Administration in Finance and a Ph.D. in Molecular Biology from the University of Michigan.
About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.
For more information: https://rallybio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
